Evidence map›Paper›PMID 38084478›Full record

ArticleBMJ global health2023

COVID-19 vaccination implementation in 52 African countries: trajectory and implications for future pandemic preparedness.

Oghenebrume Wariri, Muhammed Olanrewaju Afolabi, Christinah Mukandavire, Yauba Saidu, Obe Destiny Balogun, Sidy Ndiaye, Emmanuel A Okpo, Terna Nomhwange, Olalekan A Uthman, Beate Kampmann

Abstract read
In one paragraph

Article in BMJ global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Oghenebrume Wariri *Vaccines and Immunity Theme, MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia Muhammed.Afolabi@lshtm.ac.uk owariri@mrc.gm.ORCID 0000-0002-7432-8995
Muhammed Olanrewaju Afolabi *Vaccine Centre, London School of Hygiene and Tropical Medicine, London, UK Muhammed.Afolabi@lshtm.ac.uk owariri@mrc.gm.ORCID 0000-0002-9967-6419
Christinah MukandavireDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Yauba SaiduClinton Health Access Initiative, Yaounde, Cameroon.
Obe Destiny BalogunDoctors Pharmacy, Lima, Ohio, USA.
Sidy NdiayeWHO Regional Office for Africa, Brazzaville, Republic of Congo.
Emmanuel A OkpoUK Health Security Agency, Newcastle upon Tyne, UK.
Terna NomhwangeImmunization, WHO Country Office for Nigeria, Abuja, Nigeria.ORCID 0000-0002-1563-4351
Olalekan A UthmanDivision of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.ORCID 0000-0002-8567-3081
Beate KampmannVaccines and Immunity Theme, MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Funding

Medical Research Council MC_UU_00026/2Medical Research Council MR/R005990/2Medical Research Council MR/S03286X/1World Health Organization 001
6 · The paper itself

Abstract

introductionTo end the COVID-19 pandemic, the WHO set a goal in 2021 to fully vaccinate 70% of the global population by mid-2022. We projected the COVID-19 vaccination trajectory in 52 African countries and compared the projected to the 'actual' or 'observed' coverage as of December 2022. We also estimated the required vaccination speed needed to have attained the WHO 70% coverage target by December 2022.

methodsWe obtained publicly available, country-reported daily COVID-19 vaccination data, covering the initial 9 months following the deployment of vaccines. We used a deterministic compartmental Susceptible-Exposed-Infectious-Recovered-type model and fit the model to the number of COVID-19 cases and vaccination coverage in each African country using a Markov chain Monte Carlo approach within a Bayesian framework.

findingsOnly nine of the 52 African countries (Tunisia, Cabo Verde, Lesotho, Mozambique, Rwanda, Seychelles, Morocco, Botswana and Mauritius) were on track to achieve full COVID-19 vaccination coverage rates ranging from 72% to 97% by the end of December 2022, based on their progress after 9 months of vaccine deployment. Of the 52 countries, 26 (50%) achieved 'actual' or 'observed' vaccination coverage rates within ±10 percentage points of their projected vaccination coverage. Among the countries projected to achieve <30% by December 2022, nine of them (Chad, Niger, Nigeria, South Sudan, Tanzania, Somalia, Zambia, Sierra Leone and Côte d'Ivoire) achieved a higher observed coverage than the projected coverage, ranging from 12.3 percentage points in South Sudan to 35.7 percentage points above the projected coverage in Tanzania. Among the 52 countries, 83% (43 out of 52) needed to at least double their vaccination trajectory after 9 months of deployment to reach the 70% target by December 2022.

conclusionOur findings can guide countries in planning strategies for future global health emergencies and learning from each other, especially those that exceeded expectations and made significant progress towards the WHO's 2022 COVID-19 vaccination target despite projected poor coverage rates.

Indexed as

COVID-19VaccinesBayes TheoremCOVID-19 VaccinesHumansPandemicsTanzaniaVaccinationCOVID-19 VaccinesVaccinesCOVID-19ImmunisationVaccines

Identifiers

PMID38084478
PMCPMC10711863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.